Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
• Subjects must be able to read and speak English or Spanish at the 8th grade level.
Locations
United States
Florida
Moffitt Cancer Center
RECRUITING
Tampa
Contact Information
Primary
Daniel Lastorino
Daniel.Lastorino@moffitt.org
813-745-0092
Time Frame
Start Date: 2025-06-05
Estimated Completion Date: 2028-06
Participants
Target number of participants: 100
Treatments
Bruton's tyrosine kinase inhibitor treatment
Patients treated with a Bruton's tyrosine kinase inhibitor.
B-Cell Lymphoma 2 Protein Inhibitor treatment
Patients treated with a B-Cell Lymphoma 2 Protein Inhibitor.
Related Therapeutic Areas
Sponsors
Leads: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: AstraZeneca, National Comprehensive Cancer Network